Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades
Analysts have upgraded Sweetgreen, Target, and Airbnb, citing reasons such as easing health concerns, improved traffic, and growth potential. Conversely, Liquidia and FICO have faced downgrades due to patent disputes and increased competition, respectively. These shifts highlight changing market perceptions across various sectors.
Stocktwits Wall Street Wrap: Analysts Turn Bullish On Sweetgreen, Target And Airbnb – Liquidia And FICO Face Downgrades
Analysts are turning bullish on Sweetgreen, Target, and Airbnb due to improving traffic, turnaround efforts, and growth potential, respectively. Conversely, Liquidia and FICO are facing downgrades due to patent disputes and increased competition from alternative credit scoring models. Sea Ltd. also received a downgrade due to rising spending hurting margins and increasing competition.
Liquidia Shares Tank On Patent Court Loss, Rivals May Just Be Getting Started
Liquidia shares plummeted over 60% after a patent court ruled that its flagship drug, Yutrepia, infringed on valid claims of United Therapeutics' 327 patent. This ruling creates significant uncertainty for Yutrepia's commercial future, despite its strong Q2 2026 revenue of $170.4 million. The company now awaits the court's decision on remedies, which could severely impact its market position and valuation.
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia
United Therapeutics shares surged 13% after a Delaware federal judge ruled that Liquidia's Yutrepia infringed two valid patent claims related to inhaled treprostinil for PH-ILD, causing Liquidia's stock to drop over 50%. The court invalidated four other claims, and both companies have one week to propose remedies, with United Therapeutics seeking withdrawal of Yutrepia's approval and damages, while Liquidia plans to appeal. An analyst upgraded United Therapeutics to Buy with a $728 target following the decision.
Liquidia Corp. Shares Edge Higher After Hours - United Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA)
Liquidia Corp. shares saw an after-hours increase despite a federal court ruling in favor of United Therapeutics regarding patent infringement related to Liquidia's Yutrepia product. The court found two claims of United Therapeutics' patent valid and infringed, leading to uncertainty for Liquidia's product, particularly concerning the PH-ILD indication. Liquidia plans to appeal the decision and submit a supplement to remove PH-ILD from Yutrepia's label.
Liquidia Stock Extends Slide Following US Court Ruling in Patent Dispute
Liquidia stock is extending its slide following a U.S. District Court ruling in a patent dispute with United Therapeutics. The court found claims 1 and 14 of United Therapeutics' patent valid and infringed by Liquidia regarding its Yutrepia marketing for PH-ILD, while invalidating four other claims. Liquidia plans to appeal and may submit a supplement to the FDA to remove PH-ILD from Yutrepia's label.
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
United Therapeutics Corporation announced a victory in a patent infringement lawsuit against Liquidia Technologies, Inc. The U.S. District Court for the District of Delaware found that Liquidia infringed on United Therapeutics' patent related to the use of inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and failed to prove the patent invalid. United Therapeutics anticipates an order for the FDA to withdraw approval of Liquidia's Yutrepia for the PH-ILD indication and plans to seek monetary damages.
A court found Liquidia infringed two patent claims. Its inhaled treatment could face limits.
A District Court ruled that Liquidia (LQDA) infringed two patent claims related to its YUTREPIA inhalation powder, specifically claims 1 and 14 of U.S. Patent No. 11,826,327, which cover treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The remedy for this infringement is still undecided, with potential restrictions ranging from removing the PH-ILD indication from YUTREPIA's label to broader limits on product availability. Liquidia plans to appeal the decision and submit an FDA application supplement to remove the PH-ILD indication, acknowledging that financial exposure and potential outcomes cannot yet be reasonably estimated.
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia's shares plummeted nearly 50% after a federal court ruled its lung drug, Yutrepia, infringed on a key patent held by rival United Therapeutics. This decision deals a significant blow to Yutrepia's commercial prospects and strengthens the market position of United Therapeutics' blockbuster drug, Tyvaso, whose shares rose over 12%. Liquidia plans to appeal the ruling and ask the FDA to remove the PH-ILD indication from Yutrepia's label.
Liquidia Corporation Announces District Court Ruling on United Therapeutics Patent Claims for YUTREPIA
Liquidia Corporation announced that the U.S. District Court for Delaware has ruled that two claims of United Therapeutics Corporation's patent, related to Liquidia's YUTREPIA for treating pulmonary hypertension associated with interstitial lung disease, are valid and infringed. Liquidia's CEO expressed disagreement and plans to appeal while also pursuing a label modification for YUTREPIA to remove the PH-ILD indication. The court has given both parties one week to propose remedies, which could impact YUTREPIA's market availability.
Liquidia shares crater after court rules for United Therapeutics
Liquidia Corp. shares fell after a U.S. District Court ruled that the company infringed on two patent claims held by United Therapeutics Corp., which subsequently saw its shares rise. The court determined that claims 1 and 14 of U.S. Patent No. 11,826,327 were infringed by Liquidia, covering the treatment of pulmonary hypertension with interstitial lung disease. Liquidia plans to appeal the decision and intends to remove the PH-ILD indication from YUTREPIA's label.
Liquidia plunges after court ruling in United Therapeutics patent fight (LQDA:NASDAQ)
Liquidia Corporation's stock plummeted by 52% following a court ruling in its patent dispute with United Therapeutics concerning its Yutrepia drug. The court denied Liquidia's motion to strike, indicating a setback for Liquidia. Conversely, United Therapeutics saw a 13% increase in its stock as the decision strengthens its intellectual property around its treprostinil franchise.
Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 Patent
Liquidia Corporation announced an update on its Hatch-Waxman litigation with United Therapeutics regarding the ‘327 patent, which covers treprostinil treatment for PH-ILD. The U.S. District Court found two claims of the patent valid and infringed by Liquidia, while other asserted claims were deemed invalid. Liquidia plans to appeal the decision and will submit a supplement to YUTREPIA’s New Drug Application to remove PH-ILD from the label, though potential remedies and financial exposure remain uncertain.
Liquidia rises 8% amid broader strength in biotech peers (LQDA:NASDAQ)
Shares of Liquidia Corporation (LQDA) climbed nearly 8% on Monday, closing at $73.67, despite a down day for the overall market. This increase was attributed to broader strength in the healthcare sector, the FDA Fast Track Designation for YUTREPIA, and positive sector momentum. However, analysts have concerns regarding slower YUTREPIA prescriber growth, competition, valuation, and ongoing patent litigation.
Liquidia Corporation (NASDAQ:LQDA) Stock Rated "Hold" by Wall Street Brokerages
Liquidia Corporation (NASDAQ:LQDA) has received an average "Hold" recommendation from Wall Street brokerages, with an average 12-month price target of $98.08. The company recently reported significant year-over-year revenue growth of 1842.1% to $171.68 million, although its quarterly EPS of $0.74 slightly missed the consensus estimate of $0.76. Insider selling activity was noted, with 622,519 shares sold worth approximately $48.1 million in the last quarter, while institutional investors hold 64.54% of the stock.
Form 144 LIQUIDIA CORPORATION For: 22 September By Investing.com
This article announces the filing of Form 144 for LIQUIDIA CORPORATION on September 22. It is a brief, one-line report from Investing.com, providing basic information about the SEC filing. The company's stock symbol LQDA is mentioned along with a slight increase in its percentage.
Liquidia (NASDAQ:LQDA) Rating Increased to Buy at Wall Street Zen
Wall Street Zen upgraded Liquidia (NASDAQ:LQDA) from a "Hold" to a "Buy" rating. Despite this, the broader analyst consensus for Liquidia remains "Hold," with an average price target of $98.08. The company's stock opened at $66.88, down 2.2%, with a market capitalization of $5.99 billion, and reported significant year-over-year revenue growth of 1,842.1% in its latest quarter, though EPS narrowly missed estimates.
Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Quality
Liquidia (NASDAQ:LQDA) is identified as a biopharmaceutical company with exceptional fundamental growth, a solid health profile, and a consolidating chart pattern, making it a candidate for breakout strategies. The company shows significant revenue and EPS growth, strong margins, and a low bankruptcy risk. While the short-term technical trend is negative, the stock's relative strength and consolidation above support suggest potential for future upside if resistance is reclaimed.
Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 9,024 Shares
Liquidia Director Raman Singh sold 9,024 shares of LQDA stock for $619,226.88 on September 11th, and an additional 8,468 shares for $560,242.88 on September 14th, significantly reducing his stake. The company reported strong revenue growth but narrowly missed earnings estimates, leading to a mixed "Hold" consensus rating from analysts. Institutional investors hold 64.54% of the company, which specializes in biopharmaceuticals for cardiopulmonary conditions.
Option exercises and share sales by Liquidia (NASDAQ: LQDA) director
Liquidia Corp director Raman Singh exercised options and sold a total of 17,492 common shares in September 2026. The shares were sold at prices significantly higher than the exercise prices of the options, with proceeds totaling approximately $1.18 million. The transactions were reported in a Form 4 filing, which also noted 5,882 unvested restricted stock units still held by the director.
Squarepoint Ops LLC Trims Stock Position in Liquidia Corporation $LQDA
Squarepoint Ops LLC significantly reduced its stake in Liquidia Corporation by 81.8% in Q2, selling over 132,000 shares but still holding 29,422 shares valued at $2.35 million. This divestment occurred amidst broader insider selling, with Liquidia's directors and CEO collectively selling approximately $54.5 million in stock over the last 90 days, despite the company reporting robust revenue growth. Institutional investors currently own 64.54% of Liquidia, and analyst sentiment is mixed, with a consensus "Hold" rating.
Liquidia (NASDAQ:LQDA) Rating Lowered to "Hold" at Wall Street Zen
Liquidia (NASDAQ:LQDA) has been downgraded from a "Buy" to a "Hold" rating by Wall Street Zen, a decision echoed by Zacks Research and Lifesci Capital, aligning with MarketBeat's consensus "Hold" rating and an average price target of $98.08. The company recently reported significant quarterly revenue growth of 1,842.1% year-over-year, reaching $171.68 million, but narrowly missed earnings estimates. Insider transactions show substantial selling activity, with 790,089 shares sold for approximately $60.5 million over the past 90 days.
Director at Liquidia (NASDAQ: LQDA) plans $619K stock sale
Liquidia Corp (LQDA) director Ramandeep Singh has filed a Rule 144 notice to sell 9,024 shares of common stock, valued at $619,209.73. The proposed sale date is September 11, 2026, and is tied to a stock option exercise. This transaction will take place on NASDAQ.
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia Corporation (LQDA) has seen its stock drop by 13.9% in the last month, underperforming the industry, sector, and S&P 500. Despite its lead drug Yutrepia gaining market traction and driving profitable quarters, the company faces significant risks including over-reliance on Yutrepia, ongoing patent litigation with United Therapeutics, competitive pressures, an elevated valuation, and rising R&D costs. Consequently, Zacks Investment Research recommends avoiding LQDA stock due to its unfavorable risk-reward profile.
Liquidia Corporation $LQDA Holdings Decreased by Opaleye Management Inc.
Opaleye Management Inc. reduced its stake in Liquidia Corporation (NASDAQ:LQDA) by 3.8% in the second quarter, selling 97,500 shares but retaining 2.45 million shares valued at $195.1 million, making Liquidia its largest holding. Despite reporting a significant 1,842% year-over-year revenue increase to $171.7 million, Liquidia missed EPS estimates at $0.74. The stock opened down 1.8% at $67.85, with institutional investors owning 64.54% and insiders having sold $60.5 million in shares recently.
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia Corporation (LQDA) recently received Fast Track designation from the FDA for its drug Yutrepia (treprostinil) inhalation powder for Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). This designation facilitates accelerated development and review, and Liquidia plans to initiate a Phase IIa study in October 2026 to explore this new indication. The company is seeking to broaden Yutrepia's growth beyond its current PAH approval, facing significant competition in the pulmonary arterial hypertension market from companies like United Therapeutics and Insmed.
LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screen
LIQUIDIA CORP (NASDAQ:LQDA) has been identified as fitting the "Affordable Growth" screen due to its strong growth metrics and reasonable valuation. The company shows exceptional revenue and EPS growth, with analysts projecting continued momentum. Despite a seemingly high trailing P/E, its forward valuation and other metrics appear attractive when compared to industry peers, supported by solid financial health and acceptable profitability scores.
Wellington Management Group LLP Sells 22,925 Shares of Liquidia Corporation $LQDA
Wellington Management Group LLP reduced its stake in Liquidia Corporation (NASDAQ:LQDA) by 11.5% in the second quarter, selling 22,925 shares and retaining 176,135 shares valued at $14 million. Institutional investors now collectively own 64.54% of LQDA. Despite a significant 1,842% year-over-year increase in quarterly revenue to $171.68 million, Liquidia missed adjusted earnings expectations.
Liquidia Corp CHRO Sarah Krepp Sells 274 Shares Under Pre-Set 10b5-1 Trading Plan
Liquidia Corp's Chief Human Resource Officer, Sarah Krepp, sold 274 shares of the company's common stock on September 1, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold at a volume-weighted average price of $67.7603 to cover tax liabilities related to the settlement of Restricted Stock Units (RSUs). Following this transaction, Krepp beneficially owns 117,308 shares, including various unvested RSU tranches and shares from an employee stock purchase plan.
Liquidia Corporation (NASDAQ:LQDA) Given Consensus Recommendation of "Hold" by Analysts
Liquidia Corporation (NASDAQ:LQDA) has received a consensus "Hold" rating from eleven analysts, with an average 12-month price target of $98.08. The company recently reported quarterly revenue of $171.68 million, exceeding estimates, but narrowly missed EPS expectations. Despite significant insider selling, institutional investors hold a majority stake, with notable recent purchases from entities like California State Teachers Retirement System.
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Liquidia Corporation announced it will present two posters at the European Respiratory Society (ERS) 2026 Congress in Barcelona, Spain. The presentations will focus on their inhaled treprostinil programs, including YUTREPIA for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and the investigational L606 for PH-ILD. Dr. Rajeev Saggar, Chief Medical Officer, highlighted the importance of these steps in building evidence for treatments that could significantly improve care for patients with PH-ILD.
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation announced that its COO & CFO, Michael Kaseta, and CBO, Jason Adair, will present a business update at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. The presentation will be a fireside chat accessible via webcast on Liquidia's investor relations website, with a replay available for 30 days. Liquidia is a biopharmaceutical company focused on respiratory and vascular diseases, developing therapies using its proprietary PRINT® technology.
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation announced that its Chief Operating Officer and Chief Financial Officer, Michael Kaseta, and Chief Business Officer, Jason Adair, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. They will provide a business update on Tuesday, September 8, 2026, at 8:45 a.m. ET. A webcast of the event will be accessible via the company's investor relations website.
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Liquidia Corporation announced that its Chief Operating Officer and Chief Financial Officer, Michael Kaseta, and Chief Business Officer, Jason Adair, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026. They will provide an update on the company's business. A webcast of the event will be available on Liquidia's investor relations website.
Liquidia Corporation $LQDA Shares Bought by Seven Fleet Capital Management LP
Seven Fleet Capital Management LP significantly increased its stake in Liquidia Corporation (NASDAQ:LQDA) by 25.2% in the second quarter, now holding 256,603 shares valued at approximately $20.5 million. Despite this institutional interest and substantial year-over-year revenue growth of 1,842.1%, analyst sentiment remains mixed with a consensus "Hold" rating, and company insiders have sold a significant amount of stock recently. Liquidia, a clinical-stage biopharmaceutical company, focuses on improving drug delivery through its proprietary PRINT® platform, with its lead candidate LIQ861 targeting pulmonary arterial hypertension.
Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 73,631 Shares of Stock
Liquidia (NASDAQ:LQDA) insider Jason Adair sold 73,631 shares of the company's stock for approximately $5.09 million at an average price of $69.09. This transaction, executed under a pre-arranged Rule 10b5-1 plan, reduced his stake by 29.66% to 174,606 shares. Despite missing earnings expectations slightly, Liquidia reported a significant revenue increase of 1,842.1% year-over-year to $171.68 million, and analysts have raised price targets while maintaining a "Hold" consensus rating.
Will LQDA's Differentiated PAH Approach Drive Growth?
Liquidia Corporation (LQDA) is a biopharmaceutical company focused on therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), primarily through its drug Yutrepia. Yutrepia, an inhaled dry-powder formulation, has seen strong adoption and sales since its launch in June 2025, driven by its proprietary PRINT technology. Despite significant competition in the PAH market from companies like United Therapeutics and Johnson & Johnson, Liquidia plans to expand Yutrepia's indications and advance its pipeline with assets like L606.
Liquidia (LQDA) Is Down 7.8% After Swing to Q2 Profit on Surging YUTREPIA Revenue - What's Changed
Liquidia (LQDA) swung to a Q2 profit, reporting US$74.72 million net income and US$171.68 million revenue, driven by strong YUTREPIA sales. This marks a significant shift from previous losses and indicates successful commercialization and payer access for their primary drug. Despite the positive financial performance, the stock dropped 7.8%, and the company's reliance on a single drug franchise presents a potential risk.
Liquidia(LQDA.US) Director Sells US$4.09 Million in Common Stock
A director at Liquidia (LQDA.US) recently sold 411,357 shares of common stock for a total value of US$4.09 million. The transaction occurred at an average price of US$9.94 per share. This sale is notable for its significant monetary value and the involvement of a company director.
Katherine Rielly-Gauvin Sells 18,393 Shares of Liquidia (NASDAQ:LQDA) Stock
Liquidia director Katherine Rielly-Gauvin sold 18,393 shares of Liquidia (NASDAQ:LQDA) stock for over $1.33 million, reducing her direct ownership by 29.18%. This transaction, executed under a pre-arranged Rule 10b5-1 plan, follows a previous sale of 36,789 shares on August 19th. Despite the insider selling and a recent 3.4% drop in stock price, Liquidia reported significant year-over-year revenue growth of 1842.1% and analysts maintain a consensus "Hold" rating with an average target price of $98.08.
Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin Sells 36,789 Shares of Stock
Liquidia (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 36,789 shares of the company's stock for approximately $2.76 million, reducing her direct ownership by 45.18%. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, analysts maintain a "Hold" rating with a consensus price target of $98.08, and institutional investors collectively own about 64.54% of Liquidia's outstanding shares.
Insider at Liquidia (NASDAQ: LQDA) plans multimillion-dollar stock sale
Liquidia Corporation officer Jason Adair plans to sell up to 73,631 shares of common stock, valued at approximately $5.2 million, under Rule 144. These shares were acquired through stock option exercises and restricted stock unit vestings. Adair has also disclosed a prior sale of 7,863 shares in the last three months.
Liquidia (NASDAQ: LQDA) director sells 55K shares in 10b5-1 trades
Liquidia Corp (LQDA) director Katherine Rielly-Gauvin exercised non-qualified stock options for 55,182 shares and subsequently sold them in open-market transactions on August 19–20, 2026, under a Rule 10b5-1 trading plan. The shares were sold at volume-weighted average prices of $74.9941 and $72.2273. After these transactions, her direct holdings include 44,637 shares of common stock and 5,882 unvested restricted stock units.
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tel
Liquidia Corp (LQDA) shares fell 5.8% to $71.05, despite a 106% year-to-date increase, and are considered significantly undervalued according to GuruFocus's GF Value™ which estimates a fair value of $269.47. The company holds a GF Score™ of 70/100, driven by strong growth potential (10/10) and solid financial strength (7/10), but is tempered by a low profitability rank (4/10) and concerning insider selling totaling $237.9 million. Investors are advised to exercise caution due to a potential value trap and insider selling, despite the attractive valuation and growth prospects.
Liquidia Drops 5.9% Amid Sector-Wide Selling
Liquidia Corporation experienced a 5.9% drop in its stock price, closing at $70.91, amidst a broad selloff affecting specialty pharmaceutical stocks. The decline, marked by elevated trading volume, was not company-specific but mirrored similar drops among its peers, indicating a sector-wide reaction to broader market forces. Investors are advised to monitor for persistence of this weakness or any company-specific developments that could help Liquidia decouple from sector trends.
Liquidia Drops 5.9% Amid Sector-Wide Selling
Liquidia Corporation (LQDA) experienced a 5.9% drop on Thursday, closing at $70.91 per share, as specialty pharmaceutical stocks faced a broad selloff. The decline was accompanied by elevated trading volume, with 787,878 shares exchanged. This movement appears to be driven by broader sector dynamics rather than company-specific news, with several peers also recording significant losses.
Liquidia (NASDAQ: LQDA) officer eyes $3.7M Rule 144 stock resale
An officer of Liquidia (NASDAQ: LQDA), Rajeev Saggar, has filed a Rule 144 notice to resell 50,000 shares of common stock, valued at $3.7 million. These shares were acquired through a stock option exercise on August 19, 2026. This filing follows two previous Rule 144 sales by Saggar in the last three months, totaling 39,460 shares.
Liquidia Corp (LQDA) CMO cashes in options, unloads 79K+ shares
Liquidia Corp's Chief Medical Officer, Rajeev Saggar, exercised non-qualified stock options for 50,000 shares at $3.73 per share. Concurrently, he sold 79,534 shares of common stock in two transactions: 29,534 shares at an average price of $76.84 and 50,000 shares at an average price of $74.06. Following these transactions, Saggar still holds 150,000 stock options, along with unvested RSUs and shares from an employee stock purchase plan.
Liquidia (NASDAQ:LQDA) Insider Sells $3,703,000.00 in Stock
Liquidia insider Rajeev Saggar sold 50,000 shares of the company's stock for $3.70 million, reducing his direct ownership by 26.01%. This follows two previous sales in August and July. Despite the insider selling, Liquidia's stock traded up 1.3%, and the company reported a significant year-over-year revenue increase, although it missed earnings expectations.
Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock
Liquidia (NASDAQ:LQDA) insider Rajeev Saggar sold 29,534 shares of the company's stock on August 17th for approximately $2.27 million, reducing his stake by 17.19%. This follows previous sales of 50,000 shares on August 19th and 9,926 shares on July 13th. The company recently reported strong revenue growth but slightly missed EPS estimates, and analysts currently hold a "Hold" consensus rating with an average price target of $98.08.
